CoChat

PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease

Open access
Lee, Ji Soo, Mukhopadhyay, Partha, Matyas, Csaba, Trojnar, Eszter, Paloczi, Janos, Yang, Yuan Ru, Blank, Brandon A., Savage, Cody, Sorokin, Alexander V., Mehta, Nehal N., Vendruscolo, Janaina C. M., Koob, George F., Vendruscolo, Leandro F., Pacher, Pal, Lohoff, Falk W. · 2019 · Scientific Reports
Cited by 77

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Alcoholic liver disease (ALD) causes significant morbidity and mortality, and pharmacological treatment options are limited. In this study, we evaluated the PCSK9 inhibitor alirocumab, a monoclonal antibody that robustly reduces low-density lipoprotein cholesterol (LDL-C), for the treatment of ALD using a rat model of chronic alcohol exposure. Alirocumab (50 mg/kg) or vehicle was administered weekly for 6 weeks to rats receiving a 12% alcohol liquid diet or an isocaloric control diet. At the end of the alcohol exposure protocol, serum and liver samples were obtained for molecular characterization and histopathological analysis. PCSK9 inhibition with alirocumab attenuated alcohol-induced hepatic triglyceride accumulation through regulation of lipid metabolism (mRNA expression of modulators of fatty acid synthesis (FAS) and catabolism (PPARα and CPT1)), hepatocellular injury (ALT), hepatic inflammation (mRNA expression of pro-inflammatory cytokines/chemokines (TNFa, IL-1β, IL-22, IL-33, IL-17α, IL-2, MIP-2, and MCP-1), and neutrophil infiltration (myeloperoxidase staining)). Alirocumab treatment also attenuated alcohol-induced PCSK9 mRNA elevation and upregulated LDL-receptor (LDL-R) via modulation of the transcription factors (SREBP-1, SREBP-2, and E2F1) in liver. We demonstrated that chronic anti-PCSK9 treatment using the monoclonal antibody alirocumab attenuated alcohol-induced steatohepatitis in the rat model. Given the large unmet clinical need for effective and novel treatments for ALD, anti-PCSK9 treatment with the monoclonal antibody that spares liver metabolism is a viable new therapeutic possibility. Future studies are needed to elucidate the exact role of PCSK9 in ALD and alcohol use disorder (AUD) and to evaluate efficacy and safety of anti-PCSK9 treatment in clinical populations with ALD/AUD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-019-53603-6

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 77

Metadata

Authors
Lee, J. S., Mukhopadhyay, P., Matyas, C., Trojnar, E., Paloczi, J., Yang, Y. R., Blank, B. A., Savage, C., Sorokin, A. V., Mehta, N. N., Vendruscolo, J. C. M., Koob, G. F., Vendruscolo, L. F., Pacher, P., & Lohoff, F. W.
Venue
Scientific Reports
Published
2019-11-20
Volume
9
Issue
1
Pages
17167-17167
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2989821831
Cited by
77
References
15
FWCI
6.89
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease. https://app.cochat.ai/papers/10.1038/s41598-019-53603-6
The paper
Lee, J. S., Mukhopadhyay, P., Matyas, C., Trojnar, E., Paloczi, J., Yang, Y. R., Blank, B. A., Savage, C., Sorokin, A. V., Mehta, N. N., Vendruscolo, J. C. M., Koob, G. F., Vendruscolo, L. F., Pacher, P., & Lohoff, F. W. (2019). PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease. Scientific Reports. https://doi.org/10.1038/s41598-019-53603-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.